Evidence map›Paper›PMID 30926572›Full record

ArticleJournal of the American Academy of Child and Adolescent Psychiatry2020

Saliva MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development.

Steven D Hicks, Randall L Carpenter, Kayla E Wagner, Rachel Pauley, Mark Barros, Cheryl Tierney-Aves, Sarah Barns, Cindy Dowd Greene, Frank A Middleton

2 registry-linked trialsAbstract readMulticenter Study
In one paragraph

Article in Journal of the American Academy of Child and Adolescent Psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 53 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02832557 completednot on this map

Validation of a Salivary miRNA Diagnostic Test for Autism Spectrum Disorder

TypeobservationalSponsorState University of New York - Upstate Medical UniversityRan2015 to 2021Enrolled998ConditionsAutism Spectrum Disorder, Developmental DelayArmsSalivary collection, Vineland Adaptive Behavior Scale-III Assessment, Medical history questionaire, Autism Diagnostic Observation Schedule -2nd edition (ADOS-2), Mullen Scales of Early Learning
NCT05418023 unknown statusnot on this mapstarted 2022, after this paper: background citation

Validation of a Salivary miRNA Diagnostic Test for Autism Spectrum Disorder

TypeobservationalSponsorQuadrant Biosciences Inc.Ran2022 to 2023Enrolled6,604ConditionsAutism Spectrum Disorder, Developmental DelayArmsSalivary Collection, Adaptive Assessment, Medical and Demographic questionnaire, Autism Assessment, Intellectual Development Assessment
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Potential of Salivary Biomarkers in Autism Research: A Systematic Review.International journal of molecular sciences · 2021
    Pooled it
  5. Pooled it
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. MicroRNAs in neurodegenerative diseases: from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies-advances and challenges.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Comparison of MicroRNA Levels of 18-60-month-old Autistic Children with Those of Their Siblings and Controls.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Steven D HicksDivision of Academic General Pediatrics, Penn State College of Medicine, Hershey, PA. Electronic address: shicks1@pennstatehealth.psu.edu.
Randall L CarpenterQuadrant Biosciences, Syracuse, NY; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge.
Kayla E WagnerQuadrant Biosciences, Syracuse, NY.
Rachel PauleyNew York University, New York, NY.
Mark BarrosThe Houston Institute of Neurology for Kids, The Woodlands, TX.
Cheryl Tierney-AvesDivision of Pediatric Rehabilitation and Development, Penn State Children's Hospital, Hershey, PA.
Sarah BarnsState University of New York Upstate Medical University (SUMU), Syracuse.
Cindy Dowd GreeneQuadrant Biosciences, Syracuse, NY.
Frank A MiddletonState University of New York Upstate Medical University (SUMU), Syracuse.

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Penn State Institutional Career Development CoreKL2TR002015 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI VAN SCOY, LAUREN JODI · 2016 to 2025
$7.8M
Validation of a salivary miRNA diagnostic test for autism spectrum disorderR42MH111347 · NIMH · QUADRANT BIOSCIENCES, INC. · PI DU, QIAN, FRAZIER, THOMAS WILLIAM · 2018 to 2020
$2.2M
Validation of a salivary miRNA diagnostic test for autism spectrum disorderR41MH111347 · NIMH · QUADRANT BIOSCIENCES, INC. · PI MIDDLETON, FRANK A. · 2016 to 2016
$225k
NCATS NIH HHS KL2 TR002015NCATS NIH HHS UL1 TR002014NIMH NIH HHS R41 MH111347NIMH NIH HHS R42 MH111347
6 · The paper itself

Abstract

objectiveClinical diagnosis of autism spectrum disorder (ASD) relies on time-consuming subjective assessments. The primary purpose of this study was to investigate the utility of salivary microRNAs for differentiating children with ASD from peers with typical development (TD) and non-autism developmental delay (DD). The secondary purpose was to explore microRNA patterns among ASD phenotypes.

methodThis multicenter, prospective, case-control study enrolled 443 children (2-6 years old). ASD diagnoses were based on DSM-5 criteria. Children with ASD or DD were assessed with the Autism Diagnostic Observation Schedule II and Vineland Adaptive Behavior Scales II. MicroRNAs were measured with high-throughput sequencing. Differential expression of microRNAs was compared among the ASD (n = 187), TD (n = 125), and DD (n = 69) groups in the training set (n = 381). Multivariate logistic regression defined a panel of microRNAs that differentiated children with ASD and those without ASD. The algorithm was tested in a prospectively collected naïve set of 62 samples (ASD, n = 37; TD, n = 8; DD, n = 17). Relations between microRNA levels and ASD phenotypes were explored.

resultFourteen microRNAs displayed differential expression (false discovery rate < 0.05) among ASD, TD, and DD groups. A panel of 4 microRNAs (controlling for medical/demographic covariates) best differentiated children with ASD from children without ASD in training (area under the curve = 0.725) and validation (area under the curve = 0.694) sets. Eight microRNAs were associated (R > 0.25, false discovery rate < 0.05) with social affect, and 10 microRNAs were associated with restricted/repetitive behavior.

conclusionSalivary microRNAs are "altered" in children with ASD and associated with levels of ASD behaviors. Salivary microRNA collection is noninvasive, identifying ASD-status with moderate accuracy. A multi-"omic" approach using additional RNA families could improve accuracy, leading to clinical application. CLINICAL TRIAL REGISTRATION INFORMATION: A Salivary miRNA Diagnostic Test for Autism; https://clinicaltrials.gov/; NCT02832557.

Indexed as

Autism Spectrum DisorderAutistic DisorderMicroRNAsCase-Control StudiesChildChild, PreschoolHumansProspective StudiesSalivaMicroRNAsautismbiomarkerdiagnosismicroRNAsaliva

Identifiers

PMID30926572
PMCPMC6764899

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.